Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SARS-CoV-2 neutralising tripleVHH antibody - Immunofusion

Next Previous
Drug Profile

SARS-CoV-2 neutralising tripleVHH antibody - Immunofusion

Alternative Names: SARS-CoV-2 omicron tripleVHH neutralising antibody -Immunofusion

Latest Information Update: 09 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunofusion
  • Class Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 30 Dec 2022 Pharmacodynamics data from early research in COVID-2019 infections released by Immunofusion (Immunofusion pipeline, December 2022)
  • 27 Dec 2022 Immunofusion files for patent for humanized VHH antibody library based receptor binding domain (RBD) binders prior to December 2022 (Immunofusion pipeline, December 2022)
  • 27 Dec 2022 Early research in COVID-2019 infections in Lithuania (Parenteral) prior to December 2022 (Immunofusion pipeline, December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top